NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (“Lev” or the “Company”) (OTCBB:LEVP) announced today that it has entered into a letter agreement with the Sanquin Blood Supply Foundation (“Sanquin”), authorizing Lev to file for European marketing authorization of its lead product candidate, Cinryze™ [C1 inhibitor (human)], for the treatment of hereditary angioedema (HAE), also known as C1 inhibitor deficiency.
